WO2007133803A3 - Treatment of mycobacterial infections - Google Patents

Treatment of mycobacterial infections Download PDF

Info

Publication number
WO2007133803A3
WO2007133803A3 PCT/US2007/011722 US2007011722W WO2007133803A3 WO 2007133803 A3 WO2007133803 A3 WO 2007133803A3 US 2007011722 W US2007011722 W US 2007011722W WO 2007133803 A3 WO2007133803 A3 WO 2007133803A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
mycobacterial infections
mediated
mycobacteria
infections caused
Prior art date
Application number
PCT/US2007/011722
Other languages
French (fr)
Other versions
WO2007133803A2 (en
Inventor
Joyce A Sutcliffe
Original Assignee
Rib X Pharmaceuticals Inc
Joyce A Sutcliffe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib X Pharmaceuticals Inc, Joyce A Sutcliffe filed Critical Rib X Pharmaceuticals Inc
Publication of WO2007133803A2 publication Critical patent/WO2007133803A2/en
Publication of WO2007133803A3 publication Critical patent/WO2007133803A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis

Abstract

The present invention relates to methods for treating, reducing the risk of, and preventing mycobacterial infections, for example infections caused or mediated by Mycobacterium tuberculosis or nontuberculosis mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria, using a safe and effective amount of an antibiotic compound.
PCT/US2007/011722 2006-05-15 2007-05-15 Treatment of mycobacterial infections WO2007133803A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80077806P 2006-05-15 2006-05-15
US60/800,778 2006-05-15
US89909507P 2007-02-01 2007-02-01
US60/899,095 2007-02-01

Publications (2)

Publication Number Publication Date
WO2007133803A2 WO2007133803A2 (en) 2007-11-22
WO2007133803A3 true WO2007133803A3 (en) 2008-01-10

Family

ID=38578556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/011722 WO2007133803A2 (en) 2006-05-15 2007-05-15 Treatment of mycobacterial infections

Country Status (1)

Country Link
WO (1) WO2007133803A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2776310A1 (en) * 2009-10-13 2011-04-21 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions of radezolid and theur use in treting, preventing, or reducing the risk of microbial infections
WO2011139832A2 (en) * 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352781A2 (en) * 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
WO2004029066A2 (en) * 2002-09-26 2004-04-08 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
WO2005061468A1 (en) * 2003-12-17 2005-07-07 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
WO2006133397A2 (en) * 2005-06-08 2006-12-14 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352781A2 (en) * 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
WO2004029066A2 (en) * 2002-09-26 2004-04-08 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
WO2005061468A1 (en) * 2003-12-17 2005-07-07 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
WO2006133397A2 (en) * 2005-06-08 2006-12-14 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEIDNER-WELLS M A ET AL: "The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 12, 21 June 2004 (2004-06-21), pages 3069 - 3072, XP004841345, ISSN: 0960-894X *

Also Published As

Publication number Publication date
WO2007133803A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2007106536A3 (en) Methods for producing an immune response to tuberculosis
WO2009109532A9 (en) Use of defensins against tuberculosis
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2008115281A3 (en) Compounds for treating viral infections
WO2009140309A3 (en) Boron-containing small molecules
WO2014086749A3 (en) Composition comprising a biological control agent and an insecticide
WO2007097940A3 (en) Reca inhibitors with antibiotic activity, compositions and methods of use
WO2006063176A3 (en) Inhibition of biofilm formation using bacteriophage
WO2008153610A3 (en) Use of il-23 antagonists for treatment of infection
ZA200701629B (en) Gyrase inhibitors and uses thereof
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
WO2009085277A3 (en) Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
EP2120562A4 (en) Method and compositions for treating hiv infections
EP4143235A4 (en) Methods and compositions for treating cytokine storm infections, including covid-19, by inhibiting ccr5/ccl5 interaction
WO2010032011A8 (en) Anti-fungal therapy
WO2012103295A3 (en) Small molecule rnase inhibitors and methods of use
WO2012074725A3 (en) Immunomodulatory methods and systems for treatment and/or prevention of hypertension
WO2011139832A3 (en) Method for treating mycobacterial infections
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
WO2007133803A3 (en) Treatment of mycobacterial infections
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
WO2008105826A3 (en) Compositions compromising lysostaphin variants and methods of using the same
BRPI0808823A2 (en) composition and method for treating, reducing, ameliorating or preventing an infection.
WO2009002652A3 (en) Use of surfactants for treating mycobacterial infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07794930

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07794930

Country of ref document: EP

Kind code of ref document: A2